MYC

Myc proto-oncogene protein

48,910 patent compounds predicted against MYC, 30,678 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL179288	0.43	10/20
SCHEMBL285019	0.53	4/20
SCHEMBL225760	0.47	4/20
SCHEMBL34510	0.46	4/20
SCHEMBL194498	0.68	3/20
SCHEMBL194499	0.68	3/20
SCHEMBL194557	0.66	3/20
SCHEMBL194558	0.66	3/20
SCHEMBL71388	0.56	3/20
SCHEMBL172420	0.56	3/20
Phthalic Acid (SCHEMBL2777)	0.56	3/20
SCHEMBL228778	0.55	3/20
Phthalic Acid (SCHEMBL107835)	0.54	3/20
SCHEMBL286653	0.52	3/20
SCHEMBL183052	0.52	3/20
SCHEMBL227731	0.50	3/20
SCHEMBL193180	0.48	3/20
Phthalic Acid (SCHEMBL36441)	0.48	3/20
SCHEMBL140862	0.48	3/20
Isophthalic Acid (SCHEMBL247733)	0.48	3/20

Germline variants in MYC on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MYC gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MYC by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL	PHASE2	ACTIVE_NOT_RECRUITING
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer	PHASE1/PHASE2	RECRUITING
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;	PHASE2	COMPLETED
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer	PHASE1/PHASE2	COMPLETED
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma	PHASE2	COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma	PHASE2	COMPLETED
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders	PHASE1/PHASE2	COMPLETED
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients	PHASE2	COMPLETED
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	PHASE2	RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA	PHASE1	RECRUITING
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	PHASE1	COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies	PHASE1	RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831	nan	COMPLETED
Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma	nan	UNKNOWN
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases	nan	RECRUITING
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma	nan	RECRUITING
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis	nan	COMPLETED
Next Generation Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas	nan	COMPLETED
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma	nan	RECRUITING
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MYC binder may also engage these)

Protein	Name	Similarity
P15171	—	1.000	P15171 →
B8XIA5	—	1.000	B8XIA5 →
P52160	—	1.000	P52160 →
Q9MZT9	—	1.000	Q9MZT9 →
P09416	—	1.000	P09416 →
Q28350	—	1.000	Q28350 →
P49032	—	1.000	P49032 →
Q9MZT7	—	1.000	Q9MZT7 →
P0C0N8	—	1.000	P0C0N8 →
Q7ZVS9	—	1.000	Q7ZVS9 →
P23583	—	1.000	P23583 →
Q2HJ27	—	1.000	Q2HJ27 →
P49033	—	1.000	P49033 →
Q9MZU0	—	1.000	Q9MZU0 →
A1YG22	—	1.000	A1YG22 →
P01108	—	1.000	P01108 →
A2T7L5	—	1.000	A2T7L5 →
P06295	—	0.999	P06295 →
Q90342	—	0.999	Q90342 →
P22555	—	0.998	P22555 →
P12523	—	0.998	P12523 →
P06171	—	0.998	P06171 →
Q9MZT6	—	0.998	Q9MZT6 →
Q28566	—	0.997	Q28566 →
P68271	—	0.997	P68271 →
P06646	—	0.997	P06646 →
P49709	—	0.997	P49709 →
Q9MZT8	—	0.997	Q9MZT8 →
P21438	—	0.996	P21438 →
P68272	—	0.996	P68272 →